Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Jang, Ji Young ^a   Jeon, Yoon Kyung ^a   Choi, Yun ^a   Kim, Chul Woo ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENINE NUCLEOTIDE TRANSLOCASE 2; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 2; DNA METHYLTRANSFERASE 1; PROTEIN P53; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; TNFRSF10D PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; SENSITIZATION; SOLID TUMOR; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECT; FEMALE; GENE VECTOR; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; NUDE MOUSE; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

MUS MUSCULUS;

ADENINE NUCLEOTIDE TRANSLOCATOR 2; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 77957150645     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-262     Document Type: Article

References (41)

1. Hall MA, Cleveland JL. Clearing the TRAIL for cancer therapy. Cancer Cell 2007, 12:4-6. 10.1016/j.ccr.2007.06.011, 17613431.
2. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22:8628-8633. 10.1038/sj.onc.1207232, 14634624.
3. Huang Y, Sheikh MS. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007, 224:284-289. 10.1016/j.taap.2006.12.007, 17240413.
4. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, de Vries EGE. The clinical trail of TRAIL. Eur J Cancer 2006, 42:2233-2240. 10.1016/j.ejca.2006.03.018, 16884904.
5. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007, 25:4505-4506. 10.1200/JCO.2007.13.1011, 17906217.
6. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75. 10.1038/sj.cdd.4401187, 12655296.
7. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL?. Cancer Treat Rev 2009, 35:280-288. 10.1016/j.ctrv.2008.11.006, 19117685.
8. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004, 11(Suppl 2):S193-S206. 10.1038/sj.cdd.4401535, 15608694.
9. Palacios C, Yerbes R, López-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006, 66:8858-8869. 10.1158/0008-5472.CAN-06-0808, 16951203.
10. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005, 42:588-597. 10.1002/hep.20807, 16037944.
11. Ricci S, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007, 12:66-80. 10.1016/j.ccr.2007.05.006, 17613437.
12. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and X-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 2005, 65:7815-23. 10.1158/0008-5472.CAN-04-2749, 16140950.
13. Zhang S, Shen HM, Ong CN. Down-regulation of c-FLIP contributes to the sensitization effect of 3,3-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol Cancer Ther 2005, 4:1972-81. 10.1158/1535-7163.MCT-05-0249, 16373712.
14. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911. 10.1101/gad.13.15.1899, 10444588.
15. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001, 20:2122-33. 10.1038/sj.onc.1204282, 11360196.
16. Jang JY, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Research 2008, 10:R11. 10.1186/bcr1857, 2374967, 18267033.
17. Jänicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009, 117:219-221. 10.1007/s10549-008-0217-9, 18853248.
18. Doerner A, Pauschinger M, Badorff A, Noutsias M, Giessn S, Schulze K, Bilger J, Rauch U, Schultheiss HP. Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans. FEBS Lett 1997, 414:258-62. 10.1016/S0014-5793(97)01000-4, 9315697.
19. Luciakova K, Barath P, Poliakova D, Persson A, Nelson BD. Repression of the human adenine nucleotide translocase-2 gene in growth-arrested human diploid cells. J Biol Chem 2003, 278:30624-33. 10.1074/jbc.M303530200, 12777383.
20. Stepien G, Torroni A, Chung AB, Hodge JA, Wallace DC. Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation. J Biol Chem 1992, 267:14592-97.
21. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemair C, Kroemer G, Jacotot E, Brenner C. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 2006, 66:9143-52. 10.1158/0008-5472.CAN-05-4407, 16982757.
22. Faure Vigny H, Heddi A, Giraud S, Chautard D, Stepien G. Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Mol Carcinog 1996, 16:165-72. 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G, 8688152.
23. Chevrollier A, Loiseau D, Chabi B, Renier G, Donay O, Malthiery Y, Stepien G. ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr 2005, 37:307-16. 10.1007/s10863-005-8642-5, 16341775.
24. Chevrollier A, Loiseau D, Gautier F, Malthlery Y, Stepien G. ANT2 expression under hypoxic conditions produces opposite cell cycle behavior in 143B and HepG2 cancer cells. Mol Carcinog 2005, 42:1-8. 10.1002/mc.20059, 15486956.
25. Chevrollier A, Loiseau D, Stepien G. What is the specific role of ANT2 in cancer cells?. Med Sci (Paris) 2005, 21:156-61.
26. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997, 17(2):141-3. 10.1038/ng1097-141, 9326928.
27. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, Fried VA, Minamoto T, Alarcon-Vargas D, Pincus MR, Gaarde WA, Holbrook NJ, Shiloh Y, Ronai Z. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001, 21(8):2743-54. 10.1128/MCB.21.8.2743-2754.2001, 86905, 11283254.
28. Bauer MK, Schubert A, Rocks O, Grimm S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J Cell Biol 1999, 147:1493-1502. 10.1083/jcb.147.7.1493, 2174250, 10613907.
29. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005, 62:165-86. 10.1002/pros.20126, 15389801.
30. Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004, 24:1133-40.
31. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005, 16:1125-38.
32. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate 2004, 61:35-49. 10.1002/pros.20069, 15287092.
33. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004, 7:139-56. 10.1016/j.drup.2004.03.002, 15158769.
34. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005, 4:2026-36. 10.1158/1535-7163.MCT-05-0262, 16373718.
35. Jin Z, McDonald ER, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004, 279:35829-39. 10.1074/jbc.M405538200, 15155747.
36. Meng RD, McDonald ER, Sheikh MS, Fornace AJJ, El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000, 1:130-44. 10.1006/mthe.2000.0025, 10933923.
37. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-18. 10.1126/science.277.5327.815, 9242610.
38. Sanlioglu A, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005, 5:54-72. 10.1186/1471-2407-5-54, 1156874, 15916713.
39. Ouyang DY, Wang YY, Zheng YT. Activation of c-Jun N-terminal kinases by ribotoxic stresses. Cell Mol Immunol 2005, 2:419-425.
40. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008, 27:6245-6251. 10.1038/onc.2008.301, 18931691.
41. Yaglom JA, Ekhterae D, Gabai VL, Sherman MY. Regulation of necrosis of H9c2 myogenic cells upon transient energy deprivation: rapid deenergization of mitochondria precedes necrosis and is controlled by reactive oxygen species, stress kinase JNK, HSP72 and ARC. J Biol Chem 2003, 278:50483-50496. 10.1074/jbc.M306903200, 14523009.